Dr. Reddy's Laboratories Ltd. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

Date: October 15, 2016
Pages: 50
US$ 499.00
Dr. Reddy's Laboratories Ltd. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Publisher: BAC Reports
Report type: Strategic Report
Delivery: E-mail Delivery - PDF (on default),
Hard Copy Mail Delivery (+US$ 190.00)
ID: D4EE72F7713BEN

Download PDF Leaflet

Dr. Reddy's Laboratories Ltd. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Dr. Reddy's Laboratories Ltd. Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Dr. Reddy's Laboratories Ltd. and its competitors. This provides our Clients with a clear understanding of Dr. Reddy's Laboratories Ltd. position in the Pharmaceuticals and Biotechnology Industry.

  • The report contains detailed information about Dr. Reddy's Laboratories Ltd. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
  • Another part of the report is a SWOT-analysis carried out for Dr. Reddy's Laboratories Ltd.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
  • The Dr. Reddy's Laboratories Ltd. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
  • In the part that describes Dr. Reddy's Laboratories Ltd. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
  • Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Dr. Reddy's Laboratories Ltd. business.

About Dr. Reddy's Laboratories Ltd.

Dr. Reddy’s Laboratories Limited operates as a pharmaceutical company. The company produces active pharmaceutical ingredients and intermediates and finished dosage forms and biologics products and markets them worldwide, with a focus on India, the United States, Europe and Russia. It conducts basic research in the areas of cancer, diabetes, metabolic disorders, cardiovascular disease, inflammation and bacterial infection.


The company’s segments include Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products segments.

Global Generics Segment

This segment operates in the United States, the United Kingdom, Germany, India, Russia, Venezuela, Romania, and certain countries of the former Soviet Union (Belarus, Ukraine and Kazakhstan).


In India, the company mainly focuses on the therapeutic categories of cardiovascular, diabetes management, gastro-intestinal and pain management. As of March 31, 2009, it had a total of 184 brands in India.

New product launched during the year ended March 31, 2009, included OMEZ Insta, its brand of omeprazole powder; PECEF 200, its brand of cefpodoxime; Telsartan AM, its brand of telsartan and amlodipine; Vantej, its brand of calcium sodium phospho silicate; and Xefta, its brand of gefitinib. The company also launched Combihale, a treatment for asthma.

Competition: The company’s Global Generic segment’s principal competitors in the Indian market include Cipla Limited, Glaxo SmithKline Pharmaceuticals Limited, Ranbaxy Laboratories Limited, Nicholas Piramal India Limited, Sun Pharmaceuticals Industries Limited, Zydus-Cadila Limited, Lupin Limited, Mankind Limited, Alkem Limited, Aristo Pharma Limited, and Abbott Limited.


The company’s major brands in Russia include Omez, Nise, Ketorol and Ciprolet.

Sales: In Russia, the company sells its products to the principal national distributors directly, as well as through its wholly-owned subsidiary located in Russia, OOO Dr. Reddy’s Laboratories, Russia.

Competition: The company’s Global Generics segment’s principal competitors in the Russian market include Berlin Chemi AG, Gedeon Richter Limited, Krka, Pliva, Lek, Ranbaxy, Nycomed and Egis Pharmaceuticals Limited.

North America (United States and Canada)

In North America (the United States and Canada), the company sells generic drugs which are the chemical and therapeutic equivalents of reference brand drugs, typically sold under their generic chemical names at prices below those of their brand drug equivalents. Generic drugs are finished pharmaceutical products ready for consumption by the patient.

The company has an agreement with I-VEN Pharma Capital Limited (I-VEN) for the joint development and commercialization of generic drug products for the U.S. markets.

Sales, Marketing and Distribution Network: Dr. Reddy’s Laboratories, Inc., the company’s wholly owned subsidiary in the United States, is engaged in the marketing of its generic products in North America (the United States and Canada). During the year ended March 31, 2009, the company launched sumatriptan AG, divalproex sodium, divalproex sodium sprinkles, glycopyrrolate, ramipril, venlafaxine, nabumetone, risperidone, risperidone ODT, levetracetam, lamotrigine chewable, lamotrigine tablets, naproxen OTC and famotidine OTC.

The company has an agreement with Merck & Co., Inc. allowing it to distribute and sell authorized generic versions of finasteride and simvastatin (sold by Merck under the brand names Proscar and Zocor), upon the expiration of Merck’s patents covered by these products, provided that some other company obtains 180-day exclusivity after the expiration of the patents for either product.

During 2008, the company launched its own OTC products division and introduced ranitidine 150 mg OTC in 2007 and cetirizine 10 mg OTC in January 2008. During the year ended March 31, 2009, two more OTC products launches were made.

In April 2008, the company acquired BASF Corporation’s (BASF’s) pharmaceutical contract manufacturing business and related facility in Shreveport, Louisiana, U.S.A. This business involves the contract manu

The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.




1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History


2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units


3.1. Overview
3.2. Strengths
3.3. Weaknesses
3.4. Opportunities
3.5. Threats


4.1. Financial Statements
  4.1.1. Income Statement
  4.1.2. Balance Sheet
  4.1.3. Cash Flow
4.2. Financial Ratios
  4.2.1. Profitability
  4.2.2. Margin Analysis
  4.2.3. Asset Turnover
  4.2.4. Credit Ratios
  4.2.5. Long-Term Solvency
  4.2.6. Growth Over Prior Year
  4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot


5.1. Dr. Reddy's Laboratories Ltd. Direct Competitors
5.2. Comparison of Dr. Reddy's Laboratories Ltd. and Direct Competitors Financial Ratios
5.3. Comparison of Dr. Reddy's Laboratories Ltd. and Direct Competitors Stock Charts
5.4. Dr. Reddy's Laboratories Ltd. Industry Analysis
  5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  5.4.2. Dr. Reddy's Laboratories Ltd. Industry Position Analysis


6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events


7.1. Experts Opinion
7.2. Experts Estimates



9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors


10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix





Dr. Reddy's Laboratories Ltd. Key Facts
Management Effectiveness
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Dr. Reddy's Laboratories Ltd. Key Executives
Key Executives Biographies1
Key Executives Compensations1
Dr. Reddy's Laboratories Ltd. Major Shareholders
Dr. Reddy's Laboratories Ltd. History
Dr. Reddy's Laboratories Ltd. Products
Revenues by Segment
Revenues by Region
Dr. Reddy's Laboratories Ltd. Offices and Representations
Dr. Reddy's Laboratories Ltd. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Dr. Reddy's Laboratories Ltd. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Credit Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Dr. Reddy's Laboratories Ltd. Capital Market Snapshot
Dr. Reddy's Laboratories Ltd. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Dr. Reddy's Laboratories Ltd. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Dr. Reddy's Laboratories Ltd. Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Historical Surprises1
Revenue Estimates Trend1
Earnings Estimates Trend1
Revenue Revisions1


Dr. Reddy's Laboratories Ltd. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Dr. Reddy's Laboratories Ltd. 1-year Stock Charts
Dr. Reddy's Laboratories Ltd. 5-year Stock Charts
Dr. Reddy's Laboratories Ltd. vs. Main Indexes 1-year Stock Chart
Dr. Reddy's Laboratories Ltd. vs. Direct Competitors 1-year Stock Charts
Dr. Reddy's Laboratories Ltd. Article Density Chart

1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.

Enhanced SWOT Analysis

Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

  • How to use the strengths to take advantage of the opportunities?
  • How to use the strengths to reduce likelihood and impact of the threats?
  • How to overcome the weaknesses that obstruct taking advantage of the opportunities?
  • How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.

PESTEL Analysis

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.

Key Factors Examined by PESTEL Analysis:

  • Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
  • Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
  • Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
  • Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
  • Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
  • Legal – What laws and legislation will exert influence on the style the business is carried out?

IFE, EFE, IE Matrices

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.

Porter Five Forces Analysis

The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

  1. What composes a threat of substitute products and services?
  2. Is there a threat of new competitors entering the market?
  3. What is the intensity of competitive rivalry?
  4. How big is the bargaining power of buyers?
  5. How significant is the bargaining power of suppliers?

VRIO Analysis

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:

  • Tangible resources
    • Financial
    • Physical
    • Technological
    • Organizational
  • Intangible resources
    • Human
    • Innovation and Creativity
    • Reputation
  • Organizational capabilities

The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:

  • Valuable?
  • Rare?
  • Costly to imitate?
  • Organized properly?
Skip to top

Ask Your Question

Dr. Reddy's Laboratories Ltd. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: